Description

4-Hydroxy Fosinoprilat is a key pharmaceutical intermediate and active metabolite of the angiotensin-converting enzyme (ACE) inhibitor Fosinopril. This compound is critical for research and development in cardiovascular pharmacology, serving as a reference standard and a precursor in analytical and synthetic workflows. It is primarily utilized by pharmaceutical manufacturers, contract research organizations (CROs), and academic institutions engaged in drug metabolism studies, impurity profiling, and the development of new antihypertensive therapies.

Application

• Pharmaceutical Reference Standard: Used as a certified reference material (CRM) for the quantitative and qualitative analysis of Fosinopril and its metabolites in drug substances and finished products.
• Active Pharmaceutical Ingredient (API) Intermediate: Serves as a critical building block in the synthesis and scale-up production of Fosinopril sodium.
• Metabolite Research: Essential for in-vitro and in-vivo studies investigating the pharmacokinetics, pharmacodynamics, and metabolic pathways of ACE inhibitor drugs.
• Impurity Profiling: Employed to identify, quantify, and control related substances and degradation products during API manufacturing to ensure compliance with ICH guidelines.
• Analytical Method Development: Used to validate HPLC, LC-MS, and other chromatographic methods for potency and purity assays in quality control laboratories.
• Biochemical Research: Applied in enzymatic studies to understand the mechanism of action and inhibition kinetics of ACE inhibitors.

Basic Information

Product Name	4-Hydroxy Fosinoprilat
CAS No.	113411-10-2
Molecular Formula	C30H45NO7P
Molecular Weight	562.66 g/mol
Synonyms	Fosinoprilat Hydroxy Analog; (4S)-4-Cyclohexyl-1-[[(R)-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino](phenylphosphinyl)acetyl]-L-proline Hydroxy Derivative; 4-Hydroxy Fosinoprilic Acid; 4-OH-Fosinoprilat; Fosinopril Metabolite; SQ 32,925; SQ 32925; SQ-32925
EINECS	Contact for details

Quality Control

Our 4-Hydroxy Fosinoprilat is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including identification by spectroscopic methods (IR, NMR), purity determination by HPLC, and control of specific impurities. We provide full traceability and a Certificate of Analysis (COA) with each shipment, ensuring compliance with relevant pharmacopeial standards and customer-specific requirements for pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). The material is light-sensitive and should be handled and stored accordingly to maintain stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.2%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.